ULTRAGENYX PHARMACEUTICAL INC. Excess Stock, Shares Authorized
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Excess Stock, Shares Authorized of 275.00 million shares as of 2014-09-30, per its 10-Q filed 2014-11-10.
Discontinued › Balance Sheet › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure
us-gaap:ExcessStockSharesAuthorized · last filed 2014-11-10
- 2014-09-30: Excess Stock, Shares Authorized 275.00M shares.
- 2014-06-30: Excess Stock, Shares Authorized 275.00M shares.
- 2014-03-31: Excess Stock, Shares Authorized 275.00M shares.
| Period end | Excess Stock, Shares Authorized |
|---|---|
| 2014-09-30 | 275.00M shares 10-Q · filed 2014-11-10 |
| 2014-06-30 | 275.00M shares 10-Q · filed 2014-08-11 |
| 2014-03-31 | 275.00M shares 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |